Di-Methyl-Histone H3 (Lys18) Antibody

Histone H3 Lys18 Modifications Overview

Histone H3 lysine 18 (K18) undergoes diverse post-translational modifications (PTMs) that regulate chromatin structure and gene expression. While acetylation and ubiquitylation at K18 are well-documented, di-methylation at this residue lacks robust validation in current literature or commercial antibody catalogs .

Antibody Specificity Considerations

Antibodies targeting histone PTMs require rigorous validation due to structural similarities between modifications. For example:

• Di-Methyl-Histone H3 (Lys27) Antibody #9728 exhibits cross-reactivity with H2B di-methylated Lys5 but distinguishes between mono-/tri-methylated states .

• Acetyl-Histone H3 (Lys18) Antibody (ThermoFisher #720095) shows no cross-reactivity with methylated isoforms .

Current specificity testing methods for methylation antibodies include:

1. Peptide array screening

2. Functional ChIP validation

3. Cross-reactivity profiling against 20+ related PTMs

Biological Context of K18 Modifications

While di-methylation at K18 remains uncharacterized, other K18 modifications demonstrate critical roles:

Ubiquitylation (K18ub)

• Mediated by UHRF1 during S-phase chromatin replication

• Recruits DNMT1 to maintain DNA methylation patterns

• Regulated by USP7 deubiquitylase

Acetylation (K18ac)

• Induced by CBP/p300 following estrogen stimulation

• Coordinates with H3K23ac and H3R17me for transcriptional activation

Research Implications

The absence of validated H3K18me2 antibodies suggests:

1. Technical challenges in distinguishing K18 methylation states

2. Potential biological irrelevance of this PTM in characterized epigenetic pathways

3. Need for novel antibody development with enhanced specificity screening

Researchers investigating K18 modifications should prioritize:

• Mass spectrometry-based PTM detection

• Orthogonal validation using CRISPR/dCas9 systems

• Cross-reactivity testing against H3K14me2 and H3K23me2 isoforms